About This Deal

Gilead Sciences acquired Immunomedics, Inc. for ~$21 billion, a transaction announced in October 2020.

Acquired the maker of Trodelvy, a first-in-class Trop-2 antibody-drug conjugate approved for triple-negative breast cancer, for $88.00 per share in cash, transforming Gilead's oncology portfolio with a commercial-stage product.

Acquired the maker of Trodelvy, a first-in-class Trop-2 antibody-drug conjugate approved for triple-negative breast cancer, for $88.00 per share in cash, transforming Gilead's oncology portfolio with a commercial-stage product.

Deal Terms

Acquirer
Gilead Sciences
Target
Immunomedics, Inc.
Value
~$21 billion
Date
October 2020
Type
Full acquisition
Status
Completed

Transaction Details

Announced
October 23, 2020

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: Press release ↗

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.